Physician profile
Max C Cadena
NPI 1265938955
$3,418.83
in general payments reported to CMS, 2019-2025
7 companies · $20.09 in 2025
The $20.09 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $311 · 2023: $2,501 · 2024: $226 · 2025: $20.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,038 · Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,038.03 |
| Food and Beverage | $709.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,995.84 | 2023 | Axonics, Bulkamid |
| Boston Scientific Corporation | $581.86 | 2021-2024 | Upsylon |
| Intuitive Surgical, INC. | $383.57 | 2023-2024 | Da Vinci Surgical System |
| Coloplast Corp | $160.48 | 2022 | |
| Caldera Medical, INC | $136.82 | 2024 | Desara |
| Sumitomo Pharma America, INC. | $127.22 | 2023-2025 | Gemtesa |
| Palette Life Sciences, INC. | $33.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Cadena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.